{"id":567572,"date":"2021-10-06T13:12:02","date_gmt":"2021-10-06T13:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=567572"},"modified":"2021-10-06T13:12:02","modified_gmt":"2021-10-06T13:12:02","slug":"the-anticipated-introduction-of-emerging-therapy-by-the-leading-pharma-company-fibrogen-is-expected-to-boost-the-chemotherapyinduced-anemia-market","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/the-anticipated-introduction-of-emerging-therapy-by-the-leading-pharma-company-fibrogen-is-expected-to-boost-the-chemotherapyinduced-anemia-market_567572.html","title":{"rendered":"The anticipated introduction of emerging therapy by the leading pharma company, FibroGen is expected to boost the Chemotherapy-Induced Anemia market"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1633492162.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"The anticipated introduction of emerging therapy by the leading pharma company, FibroGen is expected to boost the Chemotherapy-Induced Anemia market\" src=\"https:\/\/www.abnewswire.com\/uploads\/1633492162.png\" alt=\"The anticipated introduction of emerging therapy by the leading pharma company, FibroGen is expected to boost the Chemotherapy-Induced Anemia market\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chemotherapy-Induced Anemia<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Due to increased research initiatives and an increase in global healthcare spending, the dynamics of the Chemotherapy-Induced Anemia market are expected to change in the coming years.<\/div>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/c3f2d42566768aa30eb5c1bdaaf6ad9e.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-anemia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Anemia market report<\/a><\/strong> examines historical and projected epidemiology and Chemotherapy-Induced Anemia market trends in the 7MM. The Chemotherapy-Induced Anemia market report also analyzes current Chemotherapy-Induced Anemia treatment practices\/algorithms, Chemotherapy-Induced Anemia market drivers, Chemotherapy-Induced Anemia market barriers, and unmet medical needs.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Important Findings from the Chemotherapy-Induced Anemia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Anemia is a common complication of both cancer treatment and the disease itself.<\/li>\n<li>Leading pharmaceutical companies such as <strong>FibroGen<\/strong> and others are working diligently to develop novel therapies for Chemotherapy-Induced Anemia.<\/li>\n<li>Key Chemotherapy-Induced Anemia therapies in the pipeline include <strong>Roxadustat<\/strong> and others.<\/li>\n<li><strong>Roxadustat (FibroGen)<\/strong> is a prolyl hydroxylase inhibitor of hypoxia-inducible factor (HIF-PHI) that promotes coordinated erythropoiesis by increasing endogenous erythropoietin, improving iron availability, and decreasing hepcidin.<\/li>\n<li>The increase in Chemotherapy-Induced Anemia market size directly results from the growing incident population of Chemotherapy-Induced Anemia patients in the 7MM.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">For more insights into the emerging treatment options, request for the sample @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chemotherapy-induced-anemia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Anemia Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy-Induced Anemia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">In oncology patients, anemia is the most common and persistent hematological abnormality. Chemotherapy-Induced Anemia (CIA) is caused by malignant invasion of normal tissue, which results in blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency due to inflammation.<\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy-Induced Anemia Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">The Chemotherapy-Induced Anemia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Ten Major Cancer Indications&rsquo; Incidence Cases<\/li>\n<li>Incidence of Ten Major Cancer Indications with Chemotherapy-Induced Anemia<\/li>\n<li>Chemotherapy-Induced Anemia Severity-Specific Incident Cases<\/li>\n<li>Chemotherapy-Induced Anemia Diagnosed and Treatable Cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Chemotherapy-Induced Anemia Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The primary goals of Chemotherapy-Induced Anemia treatment are to relieve symptoms and improve quality of life. Current Chemotherapy-Induced Anemia treatment includes packed red blood cell transfusions, erythropoietin stimulating agents (ESAs), and iron supplementation.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Find out which company is going to grab the maximum market share @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-anemia-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Anemia Market Share<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy-Induced Anemia Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Chemotherapy-Induced Anemia market are expected to change in the coming years due to increased research initiatives and an increase in global healthcare spending.<\/p>\n<p style=\"text-align: justify;\">The expected launch of <strong>Roxadustat<\/strong> by leading pharma company <strong>FibroGen<\/strong> will fuel the growth of the Chemotherapy-Induced Anemia market during the forecast period (2021&ndash;30).<\/p>\n<p style=\"text-align: justify;\"><strong>Chemotherapy-Induced Anemia Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Roxadustat: FibroGen&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia: Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Disease Overview: Chemotherapy-Induced Anemia<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia Treatment and Management<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Organizations<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.<\/p>\n<\/td>\n<td>\n<p>Case Studies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.<\/p>\n<\/td>\n<td>\n<p>Key Cross Competition<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy Induced Anemia: 7 Major Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia Market Access<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>Chemotherapy-Induced Anemia Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>Bibliography<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21.<\/p>\n<\/td>\n<td>\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>22.<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chemotherapy-induced-neutropenia-cin-market?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Chemotherapy-Induced Neutropenia Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">Get a comprehensive analysis of Chemotherapy-Induced Neutropenia pipeline therapies and key companies such as <strong>Amgen, Kyowa Hakko Kirin Co., Ltd., Teva B.V., G1 Therapeutics, Spectrum Pharmaceuticals,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=the-anticipated-introduction-of-emerging-therapy-by-the-leading-pharma-company-fibrogen-is-expected-to-boost-the-chemotherapyinduced-anemia-market\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=the-anticipated-introduction-of-emerging-therapy-by-the-leading-pharma-company-fibrogen-is-expected-to-boost-the-chemotherapyinduced-anemia-market\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chemotherapy-Induced Anemia Due to increased research initiatives and an increase in global healthcare spending, the dynamics of the Chemotherapy-Induced Anemia market are expected to change in the coming years. DelveInsight&rsquo;s Chemotherapy-Induced Anemia market report examines historical and projected epidemiology and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/the-anticipated-introduction-of-emerging-therapy-by-the-leading-pharma-company-fibrogen-is-expected-to-boost-the-chemotherapyinduced-anemia-market_567572.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-567572","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/567572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=567572"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/567572\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=567572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=567572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=567572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}